- First time a team moves for ECMO patient transfer supported by Levitronix technology
- First HeartMate II implant in Spain
- Servisitemedical as a sponsor
- Preliminary results from the first PROACT trial
NEWS
World No. 1 assist: Levitronix is gaining relevance daily in the field of neonatal and children ECMO. This is due to our health professionals' increase in demand of the advantages this technology offers:
- Portability, due to their small size and low weight
- Reliability, for being the most globally implemented assist worldwide, therefore having a great number of validated publications and results. It's the only one certified for a period of up to 30 days.
- Low thrombogenic risk, due to the 100% magnetic levitation engineering it incorporates, which reduces hemolysis to practically nonexistent levels.
- Ease of use: both doctors and nurses can enjoy a high level technology which can be handled in a very simple and intuitive way by the user.
A 20 month child in Salamanca was first connected to ECMO and later moved to Madrid, where an U.H. 12 de Octubre team which had also moved for the event continued performing appropiate care. The child today is recovered and disconnected from the ECMO which was performed to her. This was made possible by the combination of professionalism, means and experience of the U.H. 12 de Octubre medical team, along with the quality and support of Levitronix technology.
It is a pleasure for us to provide the necessary technology, and support professionals such as the U.H. 12 de Octubre team, who struggle every day investing much effort and devoting their own personal time to patient care and health improvement, frequently saving their lives.
Some media where the news has been publicized or broadcast:
PRESS:
Community of Madrid General Media Management
Community of Madrid Health Portal
TELEVISION:
Cardiolink S.L., one of the companies we work with, has reached an agreement with Thoratec, obtaining the distribution of HeartMate II exclusively for Spain.
Cardiolink and the professionals that make up this company, have years of experience in the field of assistance; they are therefore endowed with the necessary structure and resources to provide national coverage to the needs of hospitals that choose to offer their patients , assistance with the largest number of implants worldwide and the only FDA-approved.
Servisitemedical, as a Cardiolink business partner, markets this product within our area of operation.
For more information, see the manufacturer's website: www.thoratec.com or contact us.
Since the beginning, Servisitemedical is backing prestigious business schools, such as ESIC (www.esic.es) to enable training access for young people, mainly those with low income and high vocation, encouraging thus accessibility and improving day to day business training of existing and future generations of our country.
Servisitemedical has collaborated as a sponsor once again in the ESIC Global Marketing Competition.
Closings of the Global Marketing Competition:
July 2010 - More
information...
July 2011 - More
information...
Why is it crucial for any company whose values are based on excellence in education and training of future professionals, to collaborate with the ESIC Global Marketing Competition?
In January 2006, the FDA approved the first and
only IDE (investigational device exemption) on the study of
anticoagulation for a mechanical valve, which is being
carried out in the U.S., with the
Study drug therapy groups:
- Low-risk aortic patients: clopidogrel plus aspirin (81mg/day)
- High-risk aortic patients: INR 1.5-2.0 plus aspirin (81mg/day)
- Mitral patients: INR 2.0-2.5 plus aspirin (81mg/day)
- Control group: American Heart Association / American College of Cardiology standards for mechanical heart valves
Reduction of turbulence, aiming for a natural design in the On-X valve, significantly reduces the complication rate.
See the web for more information